PMN (ProMIS Neurosciences) EPS (Basic) : $-0.70 (TTM As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences EPS (Basic)?

ProMIS Neurosciences's basic earnings per share (Basic EPS) for the three months ended in Jun. 2024 was $-0.13. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.70.

ProMIS Neurosciences's EPS (Diluted) for the three months ended in Jun. 2024 was $-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.70.

ProMIS Neurosciences's EPS without NRI for the three months ended in Jun. 2024 was $-0.13. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -0.72.

During the past 3 years, the average EPS without NRI Growth Rate was -6.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, ProMIS Neurosciences's highest 3-Year average EPS without NRI Growth Rate was 35.10% per year. The lowest was -31.60% per year. And the median was 13.00% per year.

ProMIS Neurosciences EPS (Basic) Historical Data

The historical data trend for ProMIS Neurosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences EPS (Basic) Chart

ProMIS Neurosciences Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.38

-0.94

-1.69

-2.41

-1.07

ProMIS Neurosciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
EPS (Basic)	Get a 7-Day Free Trial															-0.27	-0.19	-0.19	-0.19	-0.13

ProMIS Neurosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ProMIS Neurosciences's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-13.212	-	0)	/	12.293
	=	-1.07

ProMIS Neurosciences's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.624	-	0)	/	19.771
	=	-0.13

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70

ProMIS Neurosciences (NAS:PMN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ProMIS Neurosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

23J0:Germany

Address

1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2

Website

https://www.promisneurosciences.com

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Executives

Madge K. Shafmaster	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel	officer: Chief Medical Officer	C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar	10 percent owner	33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel	director, officer: Chief Executive Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury	officer: Principal Accounting Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant	officer: Chief Operating Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman	director, officer: Chief Scientific Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan	officer: Chief Development Officer	PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams	director, officer: Chairman and CEO	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory	director	830 WINTER STREET, WALTHAM MA 02451
Neil K Warma	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman	director	4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2